A randomized, placebo-controlled phase 3 trial of the PI3K8 inhibitor leniolisib for activated PI3K8 syndrome

被引:50
作者
Rao, V. Koneti [1 ]
Webster, Sharon [1 ]
Sediva, Anna [2 ,3 ]
Plebani, Alessandro [4 ]
Schuetz, Catharina [5 ]
Shcherbina, Anna [6 ]
Conlon, Niall [7 ,8 ]
Coulter, Tanya [9 ]
Dalm, Virgil A. [10 ,11 ]
Trizzino, Antonino [12 ]
Zharankova, Yulia [13 ]
Kulm, Elaine [14 ]
Koerholz, Julia [5 ]
Lougaris, Vassilios [4 ]
Rodina, Yulia [6 ]
Radford, Kath [15 ]
Bradt, Jason [16 ]
Kucher, Klaus [17 ]
Relan, Anurag [16 ]
Holland, Steven M. [1 ]
Lenardo, Michael J. [1 ]
Uzel, Gulbu [1 ]
机构
[1] NIAID, NIH, Bethesda, MD USA
[2] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic
[3] Motol Univ Hosp, Prague, Czech Republic
[4] Univ Brescia, Azienda Socio Sanitaria Terr Spedali Civili Bresc, Dept Clin & Expt Sci, Pediat Clin, Brescia, Italy
[5] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Pediat Immunol, Dresden, Germany
[6] Dmitry Rogachev Natl Med Res Ctr Pediat Hematol O, Dept Immunol, Moscow, Russia
[7] St James Hosp, Wellcome Trust Clin Res Facil, Dublin, Ireland
[8] Trinity Coll Dublin, Dept Clin Immunol, Dublin, Ireland
[9] Belfast Hlth & Social Care Trust, Reg Immunol Serv Northern Ireland, Belfast, Antrim, North Ireland
[10] Erasmus MC, Dept Internal Med, Med Ctr, Div Allergy & Clin Immunol, Rotterdam, Netherlands
[11] Erasmus MC, Med Ctr, Dept Immunol, Rotterdam, Netherlands
[12] ARNAS Osped Civ Cristina Benfratelli Hosp, Dept Pediat Hematol & Oncol, Palermo, Italy
[13] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Minsk, BELARUS
[14] Frederick Natl Lab Canc Res, Clin Res Directorate, Bethesda, MD USA
[15] Novartis Pharmaceut UK Ltd, London, England
[16] Pharming Healthcare Inc, Warren, NJ USA
[17] Novartis Inst Biomed Res, Basel, Switzerland
基金
美国国家卫生研究院;
关键词
3-KINASE DELTA SYNDROME; PI3K-DELTA SYNDROME; IMMUNODEFICIENCY; PREDISPOSES; MUTATION; DEFECTS; CDZ173;
D O I
10.1182/blood.2022018546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) is an inborn error of immunity with clinical manifestations including infections, lymphoproliferation, autoim-munity, enteropathy, bronchiectasis, increased risk of lymphoma, and early mortality. Hyperactive PI3K delta signaling causes APDS and is selectively targeted with leniolisib, an oral, small molecule inhibitor of PI3K delta. Here, 31 patients with APDS aged >= 12 years were enrolled in a global, phase 3, triple-blinded trial and randomized 2:1 to receive 70 mg leniolisib or placebo twice daily for 12 weeks. Coprimary outcomes were differences from baseline in the index lymph node size and the percentage of naive B cells in peripheral blood, assessed as proxies for immune dysregulation and deficiency. Both primary out-comes were met: the difference in the adjusted mean change (95% confidence interval [CI]) between leniolisib and placebo for lymph node size was -0.25 (-0.38, -0.12; P = .0006; N = 26) and for percentage of naive B cells, was 37.30 (24.06, 50.54; P = .0002; N = 13). Leniolisib reduced spleen volume compared with placebo (adjusted mean difference in 3-dimensional volume [cm3], -186; 95% CI, -297 to -76.2; P = .0020) and improved key immune cell subsets. Fewer patients receiving leniolisib reported study treatment-related adverse events (AEs; mostly grades 1-2) than those receiving placebo (23.8% vs 30.0%). Overall, leniolisib was well tolerated and significant improvement over placebo was notable in the coprimary endpoints, reducing lymphadenopathy and increasing the percentage of naive B cells, reflecting a favorable impact on the immune dysregulation and deficiency seen in patients with APDS. This trial was registered at www.clinicaltrials.gov as #NCT02435173.
引用
收藏
页码:971 / 983
页数:13
相关论文
共 37 条
[1]   Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency [J].
Ahmed, Alshymaa A. ;
El Shahaway, Alia A. ;
Hussien, Sameh A. .
ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2020, 48 (06) :686-693
[2]   Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage [J].
Angulo, Ivan ;
Vadas, Oscar ;
Garcon, Fabien ;
Banham-Hall, Edward ;
Plagnol, Vincent ;
Leahy, Timothy R. ;
Baxendale, Helen ;
Coulter, Tanya ;
Curtis, James ;
Wu, Changxin ;
Blake-Palmer, Katherine ;
Perisic, Olga ;
Smyth, Deborah ;
Maes, Mailis ;
Fiddler, Christine ;
Juss, Jatinder ;
Cilliers, Deirdre ;
Markelj, Gasper ;
Chandra, Anita ;
Farmer, George ;
Kielkowska, Anna ;
Clark, Jonathan ;
Kracker, Sven ;
Debre, Marianne ;
Picard, Capucine ;
Pellier, Isabelle ;
Jabado, Nada ;
Morris, James A. ;
Barcenas-Morales, Gabriela ;
Fischer, Alain ;
Stephens, Len ;
Hawkins, Phillip ;
Barrett, Jeffrey C. ;
Abinun, Mario ;
Clatworthy, Menna ;
Durandy, Anne ;
Doffinger, Rainer ;
Chilvers, Edwin R. ;
Cant, Andrew J. ;
Kumararatne, Dinakantha ;
Okkenhaug, Klaus ;
Williams, Roger L. ;
Condliffe, Alison ;
Nejentsev, Sergey .
SCIENCE, 2013, 342 (6160) :866-871
[3]  
[Anonymous], 2021, COP
[4]  
[Anonymous], 2022, ZYD
[5]  
Begg M, 2022, PREPRINT, DOI [10.2139/ssrn.4206947, DOI 10.2139/SSRN.4206947]
[6]   Liver disturbances in activated phosphoinositide 3-kinase δ syndrome [J].
Ben-Yakov, Gil ;
Kapuria, Devika ;
Marko, Jamie ;
Cho, Min Ho ;
Pittaluga, Stefania ;
Kleiner, David Erwin ;
Koh, Christopher ;
Holland, Steven ;
Uzel, Gulbu ;
Heller, Theo .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (05) :1763-1765
[7]   Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence [J].
Bloomfield, Marketa ;
Klocperk, Adam ;
Zachova, Radana ;
Milota, Tomas ;
Kanderova, Veronika ;
Sediva, Anna .
FRONTIERS IN PEDIATRICS, 2021, 9
[8]   Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function [J].
Cannons, Jennifer L. ;
Preite, Silvia ;
Kapnick, Senta M. ;
Uzel, Gulbu ;
Schwartzberg, Pamela L. .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[9]   Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency [J].
Carpier, Jean-Marie ;
Lucas, Carrie L. .
FRONTIERS IN IMMUNOLOGY, 2018, 8
[10]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586